P-Xylene

P-Xylene

SCHEMBL1420125

Cc1ccc(C)cc1.c1cc2ccc3ccncc3c2cn1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.46
CLK1 P49759 1/20 0.46
DYRK1A Q13627 1/20 0.46
IMPDH2 P12268 1/20 0.45
MAPK10 P53779 5/20 0.43
HIPK2 Q9H2X6 1/20 0.43
KDM4E B2RXH2 2/20 0.42
TNF P01375 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
RAD52 P43351 1/20 0.42
MAOA P21397 2/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.39
LATS1 O95835 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TOP2A P11388 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Xylene SCHEMBL1419643 0.92 IMPDH2 (0.44) ACHECLK1DYRK1AIMPDH2MAPK10
SCHEMBL29569821 0.87 CLK1 (0.54) ACHECLK1DYRK1AIMPDH2MAPK10
SCHEMBL672509 0.87 CLK1 (0.54) ACHECLK1DYRK1AIMPDH2MAPK10
SCHEMBL19321773 0.86 HIPK2 (0.53) ACHECLK1DYRK1AIMPDH2MAPK10
P-Xylene SCHEMBL1420144 0.82 CYP3A4 (0.56) CLK1DYRK1AMAPK10KDM4EPOLB
O-Xylene SCHEMBL1420164 0.82 MAPK10 (0.49) ACHECLK1DYRK1AIMPDH2MAPK10
P-Xylene SCHEMBL1420261 0.80 CCR1 (0.51) ACHECLK1DYRK1AKDM4ETNF
SCHEMBL8404561 0.79 CYP2A6 (0.52) ACHECLK1DYRK1AMAPK10HIPK2
SCHEMBL17308538 0.79 MAPK10 (0.44) CLK1DYRK1AMAPK10HIPK2KDM4E
SCHEMBL29568879 0.78 IMPDH2 (0.50) CLK1DYRK1AIMPDH2MAPK10HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298737-B1 Indole compounds and organic light-emitting device including the same SAMSUNG DISPLAY CO LTD (KR) 2017-05-10 EP disclosed
US-8399880-B2 Heteroarylamine compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2013-03-19 US disclosed
US-8283057-B2 Heteroarylamine compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2012-10-09 US disclosed
EP-2298740-A1 1-H-benzo[g]indole compounds and organic lightemitting device including the same Samsung Mobile Display Co., Ltd. (KR) 2011-03-23 EP disclosed
EP-2298737-A1 Indole compounds and organic light-emitting device including the same Samsung Mobile Display Co., Ltd. (KR) 2011-03-23 EP disclosed
US-20110049494-A1 HETEROARYLAMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2011-03-03 US disclosed
US-20110049484-A1 HETEROARYLAMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110049494-A1 HETEROARYLAMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME INMT, TYR, HTT ACHE 56/4885CLK1 984/4885DYRK1A 1467/4885
US-20110049484-A1 HETEROARYLAMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME INMT, TYR, HTT ACHE 56/4885CLK1 984/4885DYRK1A 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.